Molecular Involvement and Prognostic Importance of Fms-like Tyrosine Kinase 3 in Acute Myeloid Leukemia

被引:3
作者
Shahab, Sadaf [1 ]
Shamsi, Tahir S. [1 ]
Ahmed, Nuzhat [1 ]
机构
[1] Natl Inst Blood Dis & Bone Marrow Transplantat, Karachi, Pakistan
关键词
AML; FLT3; ITDs; (TKD); leukemia-specific recognition markers; prognostic marker; INTERNAL TANDEM DUPLICATION; FLT3; GENE; MYELODYSPLASTIC SYNDROME; MYELOGENOUS LEUKEMIA; NORMAL CYTOGENETICS; MUTATIONS; ASSOCIATION; IDENTIFICATION; ACTIVATION; EXPRESSION;
D O I
10.7314/APJCP.2012.13.8.4215
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AML (Acute myeloid leukemia) is a form of blood cancer where growth of myeloid cells occurs in the bone marrow. The prognosis is poor in general for many reasons. One is the presence of leukaemia-specific recognition markers such as FLT3 (fms-like tyrosine kinase 3). Another name of FLT3 is stem cell tyrosine kinase-1 (STK1), which is known to take part in proliferation, differentiation and apoptosis of hematopoietic cells, usually being present on haemopoietic progenitor cells in the bone marrow. FLT3 act as an independent prognostic factor for AML. Although a vast literature is available about the association of FLT3 with AML there still is a need of a brief up to date overview which draw a clear picture about this association and their effect on overall survival.
引用
收藏
页码:4215 / 4220
页数:6
相关论文
共 50 条
  • [21] Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia
    Battipaglia, Giorgia
    Ruggeri, Annalisa
    Massoud, Radwan
    El Cheikh, Jean
    Jestin, Matthieu
    Antar, Ahmad
    Ahmed, Syed Osman
    Rasheed, Walid
    Shaheen, Marwan
    Belhocine, Ramdane
    Brissot, Eolia
    Dulery, Remy
    Eder, Sandra
    Giannotti, Federica
    Isnard, Francoise
    Lapusan, Simona
    Rubio, Marie-Therese
    Vekhoff, Anne
    Aljurf, Mahmoud
    Legrand, Ollivier
    Mohty, Mohamad
    Bazarbachi, Ali
    CANCER, 2017, 123 (15) : 2867 - 2874
  • [22] Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)
    Ravandi, F.
    Jilani, I.
    Estey, E.
    Kantarjian, H.
    Dey, A.
    Aguilar, C.
    Jitkaroon, C.
    Giles, F.
    O'Brien, S.
    Keating, M.
    Albitar, M.
    LEUKEMIA RESEARCH, 2007, 31 (06) : 791 - 797
  • [23] Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)
    Bhattacharya, Seemana
    Mu, Hong
    Piya, Sujan
    Zhang, Weiguo
    McQueen, Teresa
    Paradiso, Linda
    Oberkovitz, Galia
    Benami, Eyal
    Andreeff, Michael
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S273 - S273
  • [24] Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors
    Muranyi, Andrew L.
    Dedhar, Shoukat
    Hogge, Donna E.
    LEUKEMIA RESEARCH, 2010, 34 (10) : 1358 - 1365
  • [25] FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies
    Mashkani, Baratali
    Tanipour, Mohammad Hossein
    Saadatmandzadeh, Mohammad
    Ashman, Leonie K.
    Griffith, Renate
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 776 : 156 - 166
  • [26] A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia
    Bazinet, Alexandre
    Bataller, Alex
    Kadia, Tapan
    Daver, Naval
    Short, Nicholas J.
    Yilmaz, Musa
    Sasaki, Koji
    Dinardo, Courtney D.
    Borthakur, Gautam M.
    Issa, Ghayas
    Bouligny, Ian
    Pierce, Sherry
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    CANCER, 2025, 131 (06)
  • [27] Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3
    Zhang, Chunxiao
    Lam, Stephen S. Y.
    Leung, Garret M. K.
    Tsui, Sze-Pui
    Yang, Ning
    Ng, Nelson K. L.
    Ip, Ho-Wan
    Au, Chun-Hang
    Chan, Tsun-Leung
    Ma, Edmond S. K.
    Yip, Sze-Fai
    Lee, Harold K. K.
    Lau, June S. M.
    Luk, Tsan-Hei
    Li, Wa
    Kwong, Yok-Lam
    Leung, Anskar Y. H.
    CANCER, 2020, 126 (02) : 344 - 353
  • [28] FMS-like tyrosine kinase 3 inhibitors: a patent review
    Lee, Jongkook
    Paek, Seung-Mann
    Han, Sun-Young
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (04) : 483 - 503
  • [29] Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study
    Islam, Md Rashedul
    Osman, Osman I.
    Hassan, Walid M. I.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (01) : 82 - 100
  • [30] Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
    Sakaguchi, Masahiro
    Yamaguchi, Hiroki
    Kuboyama, Marika
    Najima, Yuho
    Usuki, Kensuke
    Ueki, Toshimitsu
    Oh, Iekuni
    Mori, Shinichiro
    Kawata, Eri
    Uoshima, Nobuhiko
    Kobayashi, Yutaka
    Kako, Shinichi
    Tajika, Kenji
    Shono, Katsuhiro
    Kayamori, Kensuke
    Hagihara, Masao
    Kanda, Junya
    Uchiyama, Hitoji
    Kuroda, Junya
    Uchida, Naoyuki
    Kubota, Yasushi
    Kimura, Shinya
    Kurosawa, Saiko
    Date, Kenta
    Nakajima, Nana
    Marumo, Atsushi
    Omori, Ikuko
    Fujiwara, Yusuke
    Terada, Kazuki
    Yui, Shunsuke
    Wakita, Satoshi
    Arai, Kunihito
    Kitano, Tomoaki
    Kakihana, Kazuhiko
    Kanda, Yoshinobu
    Ohashi, Kazuteru
    Fukuda, Takahiro
    Inokuchi, Koiti
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (05) : 566 - 574